Cargando…
Fibroblast Growth Factor 19 and Fibroblast Growth Factor 21 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Gastric Bypass
Background: Gastric bypass (GB) is an effective treatment for those who are morbidly obese with coexisting type 2 diabetes mellitus (T2DM) or non-alcoholic fatty liver disease (NAFLD). Fibroblast growth factors (FGFs) are involved in the regulation of energy metabolism. Methods: We investigated the...
Autores principales: | Guo, Jiun-Yu, Chen, Hsin-Hung, Lee, Wei-Jei, Chen, Shu-Chun, Lee, Shou-Dong, Chen, Chih-Yen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8839096/ https://www.ncbi.nlm.nih.gov/pubmed/35277004 http://dx.doi.org/10.3390/nu14030645 |
Ejemplares similares
-
Bile Acid and Fibroblast Growth Factor 19 Regulation in Obese Diabetics, and Non-Alcoholic Fatty Liver Disease after Sleeve Gastrectomy
por: Huang, Hsien-Hao, et al.
Publicado: (2019) -
Roux-en-Y gastric bypass surgery is effective in fibroblast growth factor-21 deficient mice
por: Morrison, Christopher D., et al.
Publicado: (2016) -
Fibroblast growth factor 21 in metabolic syndrome
por: Yang, Ming, et al.
Publicado: (2023) -
Association of fibroblast growth factor 21 with alcohol consumption and alcohol liver cirrhosis
por: Wagner-Skacel, Jolana, et al.
Publicado: (2020) -
Liver-brain axis with alcohol: Role of fibroblast growth factor 21 (FGF21)
por: Zhang, Ke, et al.
Publicado: (2023)